About this trial
According to the Pan American Health Organization (PAHO), chronic, non-communicable diseases (NCDs) are the main cause of death and disability in the world. The term, NCD refers to a group of diseases that are not primarily caused by acute infection and result in long-lasting health consequences, with significant long-term care and treatment needs. These include chronic lung diseases such as COPD and metabolic diseases such as Diabetes. Worldwide, chronic non-communicable diseases are related to physical inactivity as the main risk factor. In this sense, exercise and physical activity have become priority elements of public health, with recommendations that they be carried out with moderate intensity at least 150 minutes a week. In Colombia, exercise as an important strategy for the prevention and management of chronic non-communicable diseases, which is described in the ten-year public health plan. However, in its application in clinical practice, the evidence shows that there are few structured programs at the national or regional level, which monitor the adequate prescription of exercise as a therapeutic strategy for the control of NCDs and improvement. of functionality. Reason for which this research arises, which aims to describe the effectiveness of exercise on the frailty, body composition and functional classification of 300 patients with chronic non-communicable disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Records between 2018 and 2023
Men and women, between 60 and 90 years old.
Clinical diagnosis of COPD and/or diabetes.
Must be patient from program called "Ser más".
Disqualifiers
Records containing incomplete data
Trial population
Men and women, between 60 and 90 years old, residents in the metropolitan area, with a diagnosis of COPD and/or diabetes who entered the NCD patient care program called "Ser más".
Trial design
Cohort
Retrospective
Treatments tested in this trial
Therapeutic exercise
Other interventionDuration: 30 minutes. Frequency: Once a week. Type of excercise: Cardiovascular, strengthening and balance. Supervised by a health professional.
Treatment groups
Trial outcomes
Primary outcomes
Frailty
The data will be collected from the clinical registries which have included The Groeningen frailty test, walking speed test and single-leg support test. These variables were measured by groningen frailty indicator questionnaire. This scale categorizes patients with significant frailty when they obtain a score ≥ 4. In addition, the walking speed in 5 meters will also be taken into account, which is considered in fragility cut from 0.6 m/sec and the single-leg support time when it is \< 10 seconds. This outcome is compound by multiple measurements that will be aggregated to arrive at one reported.
Secondary outcomes
Body composition
The data will be collected from the clinical registries which have included anthropometric measurements such us Body mass index, skin folds (tricipital, abdominal and mid-thigh), waist and thigh circumference. Obesity is present when the sum of the three skin folds of fat is greater than 60 mm. This outcome is compound by multiple measurements that will be aggregated to arrive at one reported.
Cardiovascular capacity
The data will be collected from the clinical registries which have included the National Aeronautics and Space Administration (NASA) method which calculates the Vo2 max and Mets, The formula includes sex, age, BMI, Resting heart rate and physical activity coefficient self-reported. Taking as a reference that a poor physical condition occurs when the estimated maximum oxygen consumption is less than 7 units of the basal metabolic rate. This outcome is compound by multiple measurements that will be aggregated to arrive at one reported.
Other outcomes
Functional classification
The data will be collected from the clinical registries which have included the functional classification. Patients were stratified according to a FC method based on functional status, presence of risk factors, and comorbidity control. There are five possible categories: i) class 1, preserved functional status with controlled comorbidity; ii) class 2A, preserved functional status with controlled comorbidity, but with the presence of risk factors; iii) class 2B, preserved functional status with uncontrolled comorbidity; iv) class 3, altered functional status with uncontrolled comorbidity; and v) class 4, lost functional status with uncontrolled comorbidity. This outcome is compound by multiple measurements that will be aggregated to arrive at one reported.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.